Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 3:00 pm Purchase |
2022-12-31 | 13G | Mirum Pharmaceuticals, Inc. MIRM |
Rock Springs Capital Management LP | 1,795,733 4.870% |
256,919 (+16.70%) |
Filing History |
| 2023-02-14 2:58 pm Purchase |
2022-12-31 | 13G | Compass Therapeutics, Inc. CMPX |
Rock Springs Capital Management LP | 5,333,188 4.220% |
5,100 (+0.10%) |
Filing History |
| 2023-02-14 2:57 pm Unchanged |
2022-12-31 | 13G | Tempest Therapeutics, Inc. TPST |
Rock Springs Capital Management LP | 823,654 7.830% |
0 (Unchanged) |
Filing History |
| 2023-02-14 2:56 pm Unchanged |
2022-12-31 | 13G | Spruce Biosciences, Inc. SPRB |
Rock Springs Capital Management LP | 1,622,689 6.890% |
0 (Unchanged) |
Filing History |
| 2023-02-14 2:55 pm Purchase |
2022-12-31 | 13G | Mereo BioPharma Group plc MREO |
Rock Springs Capital Management LP | 31,224,485 5.340% |
25,638,864 (+459.02%) |
Filing History |
| 2023-02-14 2:54 pm Purchase |
2022-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Rock Springs Capital Management LP | 3,086,027 7.640% |
633,390 (+25.82%) |
Filing History |
| 2023-02-14 2:53 pm Purchase |
2022-12-31 | 13G | Immunocore Holdings plc IMCR |
Rock Springs Capital Management LP | 3,321,066 7.330% |
849,511 (+34.37%) |
Filing History |
| 2023-02-14 2:51 pm Purchase |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Rock Springs Capital Management LP | 136,556 5.550% |
136,556 (New Position) |
Filing History |
| 2023-02-14 2:50 pm Purchase |
2022-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
Rock Springs Capital Management LP | 2,996,592 5.450% |
2,996,592 (New Position) |
Filing History |
| 2023-02-14 2:49 pm Purchase |
2022-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
Rock Springs Capital Management LP | 3,961,249 5.940% |
99,902 (+2.59%) |
Filing History |
| 2022-04-25 3:05 pm Purchase |
2022-04-14 | 13G | Inozyme Pharma, Inc. INZY |
Rock Springs Capital Management LP | 2,452,637 6.120% |
2,452,637 (New Position) |
Filing History |
| 2022-02-15 12:44 pm Purchase |
2021-12-31 | 13G | Mereo BioPharma Group plc MREO |
Rock Springs Capital Management LP | 5,585,621 5.130% |
5,585,621 (New Position) |
Filing History |
| 2022-02-14 6:27 pm Sale |
2021-12-31 | 13G | Protara Therapeutics, Inc. TARA |
Rock Springs Capital Management LP | 0 0.000% |
-643,200 (Position Closed) |
Filing History |
| 2022-02-14 6:27 pm Sale |
2021-12-31 | 13G | F-star Therapeutics, Inc. FSTX |
Rock Springs Capital Management LP | 751,889 3.650% |
-302,343 (-28.68%) |
Filing History |
| 2022-02-14 6:26 pm Sale |
2021-12-31 | 13G | FIVE PRIME THERAPEUTICS INC FPRX |
Rock Springs Capital Management LP | 0 0.000% |
-3,041,559 (Position Closed) |
Filing History |
| 2022-02-14 6:26 pm Sale |
2021-12-31 | 13G | Chiasma, Inc. CHMA |
Rock Springs Capital Management LP | 0 0.000% |
-3,243,600 (Position Closed) |
Filing History |
| 2022-02-14 6:26 pm Sale |
2021-12-31 | 13G | Ardelyx, Inc. ARDX |
Rock Springs Capital Management LP | 0 0.000% |
-20,592,448 (Position Closed) |
Filing History |
| 2022-02-14 6:25 pm Purchase |
2021-12-31 | 13G | Sierra Oncology, Inc. SRRA |
Rock Springs Capital Management LP | 1,184,793 7.870% |
617,435 (+108.83%) |
Filing History |
| 2022-02-14 6:24 pm Sale |
2021-12-31 | 13G | Spruce Biosciences, Inc. SPRB |
Rock Springs Capital Management LP | 1,622,689 6.920% |
-8,311 (-0.51%) |
Filing History |
| 2022-02-14 6:24 pm Purchase |
2021-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
Rock Springs Capital Management LP | 2,581,299 5.370% |
1,266,925 (+96.39%) |
Filing History |